Somewhat Favorable Press Coverage Somewhat Unlikely to Impact C.R. Bard (BCR) Stock Price

News articles about C.R. Bard (NYSE:BCR) have trended somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. C.R. Bard earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 46.1193367145509 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s rankings:

C.R. Bard (NYSE BCR) traded up $0.88 during trading hours on Monday, hitting $332.28. 1,425,800 shares of the company traded hands, compared to its average volume of 664,414. C.R. Bard has a twelve month low of $220.84 and a twelve month high of $337.73. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $24,280.00, a PE ratio of 43.78, a PEG ratio of 2.53 and a beta of 0.52.

C.R. Bard (NYSE:BCR) last released its earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.06. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The business had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. During the same period last year, the business earned $2.64 earnings per share. The firm’s revenue was up 5.1% on a year-over-year basis. research analysts predict that C.R. Bard will post 11.89 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be given a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. C.R. Bard’s dividend payout ratio (DPR) is 10.28%.

Several analysts have commented on the stock. ValuEngine downgraded shares of C.R. Bard from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Barclays raised their price target on shares of C.R. Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research note on Monday, November 6th. Cowen reaffirmed a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research note on Friday, November 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. Finally, Jefferies Group reaffirmed a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research note on Thursday, September 14th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $303.50.

In other C.R. Bard news, VP Frank Lupisella, Jr. sold 9,173 shares of the company’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $325.00, for a total value of $2,981,225.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Frank Lupisella, Jr. sold 7,035 shares of the company’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $334.70, for a total value of $2,354,614.50. Following the completion of the transaction, the vice president now owns 13,824 shares of the company’s stock, valued at approximately $4,626,892.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 224,139 shares of company stock valued at $73,481,664. Company insiders own 0.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.com-unik.info/2017/12/25/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-c-r-bard-bcr-stock-price.html.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C.R. Bard (NYSE:BCR)

What are top analysts saying about C.R. Bard? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for C.R. Bard and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit